NLRP3 and neoplasm: It remains to be investigated how NLRP3 deficiency, and IL-18R and IL-1R signaling affect the earlier phases of T-cell motility, such as the T-cell scanning of APC in lymph nodes, CTL egress, or entry from the blood stream into tumor tissue.